Opinion

Video

Overview of Novel Treatments for Retinal Vascular Diseases

A panelist discusses novel treatments for retinal vascular diseases, including faricimab, aflibercept, and port delivery system with ranibizumab.

Video content above is prompted by the following:
Could you briefly provide an overview of the new treatments available for retinal vascular diseases?

  1. Faricimab
  2. Aflibercept 8mg
  3. port delivery system with ranibizumab

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
(mage credit: Ophthalmology Times) S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
Related Content
(Image credit: SeeWhatMatters)
August 19th 2025

Q&A: AEVR's executive director on #SeeWhatMatters and safeguarding the National Eye Institute

3 Things You Should Know About the GA Pipeline
August 19th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/InkInvent) FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy
August 19th 2025

FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 19th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/zabhie) AI applications in cataract surgery: A surgeon’s perspective
August 19th 2025

AI applications in cataract surgery: A surgeon’s perspective

(Image credit: AdobeStock/NicoElNino) Dialing in precision: Astigmatism management with arcuate incisions
August 19th 2025

Dialing in precision: Astigmatism management with arcuate incisions

© 2025 MJH Life Sciences

All rights reserved.